# 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

> **NCT01563354** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 124 (actual)

## Conditions studied

- Neuroendocrine Carcinoma of the Lung and Thymus

## Interventions

- **DRUG:** Pasireotide LAR
- **DRUG:** Everolimus
- **DRUG:** Pasireotide LAR and Everolimus Combination

## Key facts

- **NCT ID:** NCT01563354
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-16
- **Primary completion:** 2020-02-10
- **Final completion:** 2020-02-10
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2021-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01563354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01563354, "3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01563354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*